News Image

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

Provided By GlobeNewswire

Last update: Jun 27, 2025

Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosuppression, with potent and antigen-specific anti-pancreatic cancer activities at dose levels that are well tolerated

Read more at globenewswire.com

HCW BIOLOGICS INC

NASDAQ:HCWB (8/18/2025, 3:20:04 PM)

3.95

-0.14 (-3.42%)



Find more stocks in the Stock Screener

Follow ChartMill for more